Prometheus company markets several drugs that treat gastrointestinal disorders, such as irritable bowel syndrome and ulcerative colitis. Its Entocort, which it co-promotes with AstraZeneca, is a steroid that reduces the bowel inflammation associated with Crohn's disease. Prometheus Laboratories markets its products mainly to US gastroenterologists. It also pairs its drug offerings with a diagnostic testing service that helps doctors differentiate between various gastrointestinal diseases and prescribe the right Prometheus remedy; it runs all of its tests at its San Diego lab facility. Prometheus company plans to conduct an IPO.

The Micron Group delves deeply into the world of drug discovery. Composed of companies based in the UK, the US, and South Africa -- including Micron Research, the group's flagship unit -- the group provides consulting services for pharmaceuticals research, development, and delivery companies. With expertise in Phase I-IV drug discovery trials, clinical research, data delivery, medical education, and medical communications, the group's services range from clinical development and research to marketing, strategic planning, and report publishing. The Micron Group also offers its SILK software for managing pharmaceutical R&D and marketing processes. Clients include Bristol-Myers Squibb and the World Health Organization.

Ortho-McNeil, a subsidiary of gigantic healthcare company Johnson & Johnson, makes a variety of women's health and contraceptive products. A division of Ortho-McNeil-Janssen Pharmaceuticals, its women's health line is dominated by oral contraceptives, including Ortho-cyclen, Ortho-novum, and Modicon; other products include Ditropan for overactive bladder treatment and yeast infection drug Terazol. Sister company Ortho-McNeil Neurologics was created to hold Ortho-McNeil's central nervous system drugs, including epilepsy treatment Topamax, pain management drug Ultracet, Alzheimer's treatments, and migraine remedies, allowing the company to focus strictly on women's health.

ChemoCentryx is focused exclusively on the discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemoattractant receptors. Since its founding, ChemoCentryx has established one of the broadest pipelines of chemokine-based therapeutics in the pharmaceutical industry. This has been based on our pioneering insight into the chemokine system, a complex network of chemokine (CHEMO-attractant cytoKINE) molecules (ligands) and receptors that work together to regulate the movement of immune cells in and out of inflamed tissues. Each of our novel small molecule product candidates is designed to target a specific chemokine or chemoattractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

DUSA Pharmaceuticals, Inc. was founded in 1991 and is based in Wilmington, Massachusetts. DUSA Pharmaceuticals, Inc., an integrated dermatology pharmaceutical company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions in the United States and internationally. Its products include Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The BLU-U is used without Levulan to treat moderate inflammatory acne vulgaris and general dermatological conditions. The company is also developing non-PDT drug products, including Nicomide, Nicomide-T, AVAR products, ClindaReach, Meted, and Psoriacap products.

Abaxis was founded in 1989 and is headquartered in Union City, California. Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements in the medical and veterinarian markets worldwide. Its products include Point-Of-Care Blood Chemistry Analyzer, which performs a panel of 14 tests on human patients and 13 tests on veterinary patients marketed under the Piccolo xpress and Piccolo Classic names in the human medical market and under the VetScan VS2 and VetScan Classic names in the veterinary market. The company's products also include Reagent Discs that handle various technical steps of blood chemistry testing automatically; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, which offer blood count analysis for veterinary applications. In addition, its products comprise VetScan VSpro that assists in the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, evaluation of disseminated intravascular disease, hepatic disease and monitoring therapy, and progression of disease states; and VetScan Canine Heartworm Rapid Test, a test for the detection of dirofilaria immitis in canine whole blood, serum, or plasma. Further, Abaxis's products consist of Orbos Discrete Lyophilization Process, which allows the production of active chemical ingredient in the form of a soluble bead, as well as involves in flash-freezing a drop of liquid reagent to form a solid bead and then freeze-drying the bead to remove water. The company markets and sells its products through a direct sales force in the United States and through independent distributors.

Cerep offers tools and knowledge to help those companies discover and develop new drugs without having to start from scratch. It also developed a library of compounds that includes promising substances and drug candidates developed with Bristol-Myers Squibb and Sanofi-Aventis. Customers use Cerep's expertise in compound profiling, computational chemistry, in vitro and in vivo pharmacology, and pharmacoinformatics to cut to the chase and develop successful drug candidates.

Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients. Dendreon’s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer.

Otsuka Pharmaceutical Europe was founded in 1998. Otsuka Pharmaceutical Europe markets drugs and health care products manufactured by its Japan-based parent, Otsuka Pharmaceutical. The company also conducts research and development of pharmaceuticals, focusing on the fields of gastroenterology, neurology, ophthalmology, and the cardiovascular system. Marketed drugs include schizophrenia treatment Abilify (through a partnership with Bristol-Myers Squibb), Adacolumn for inflammatory bowel disease, Mikelan for ocular glaucoma and hypertension, Pletal for peripheral vascular disease, and UBiT for gastrointestinal infection diagnosis.

RXi Pharmaceuticals was founded in 2003 and is based in Worcester, Massachusetts. RXi Pharmaceuticals Corporation, a discovery-stage biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on RNA interference for the treatment of human diseases in the United States and internationally. It intends to identify lead compounds and advance towards pre-clinical and clinical development programs in various therapeutic areas, including inflammatory disease; and metabolic diseases, such as obesity and obesity-related type 2 diabetes. The company was formerly known as Argonaut Pharmaceuticals, Inc. and changed its name to RXi Pharmaceuticals Corporation in 2006 before beginning operations in 2007.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.